June 2015

Newsletter-Banner

SAVE THE DATE: ACT-AD FDA/AD Allies Meeting Set for September 16

Save the date! We are excited to announce that our 8th Annual FDA/AD Allies Meeting will take place on September 16, 2015, from 10:00 a.m. to 4:00 p.m. at the Bethesda North Marriott Hotel & Conference Center (5701 Marinelli Rd, North Bethesda, MD). More details will be available in the coming weeks at act-ad.org.

ACT-AD Part of Two Sessions at BIO Convention

ACT-AD’s Executive Director Cynthia Bens participated in two sessions at this month’s 2015 BIO International Convention in Philadelphia. She was part of a panel on “The Bioethics of Drug Development: You Decide,” which explored the critical bioethical issues that innovative manufacturers confront in the modern health care ecosystem. Bens also spoke at a forum on how organizations like ACT-AD are helping to shape regulatory policy.

ACT-AD’s Bens to Participate in FDA PDUFA July 15 Meeting

Bens will also speak at a July 15 FDA public meeting in Silver Spring, Md., on the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years 2018 through 2022. The current act is set to expire in September 2017. The meeting will include brief presentations by FDA and a series of panels providing the perspectives of various stakeholder groups. Bens will highlight the work of ACT-AD in a panel focused on the patient perspective. For more information, please go here.

New Report Covers Role of Caregiver in the U.S.

A new study from ACT-AD partner the National Alliance on Caregiving and AARP puts the spotlight on caregivers and the increasing challenges they confront in the face of a growing older adult population. Caregiving in the U.S. highlights “higher-hour caregivers (at least 21 hours of care a week), caregivers who are ages 75 and over, and multicultural caregivers.” You can read the report here.

Impact Factor of Journal of Alzheimer’s Disease Increases 15 Percent

The Journal of Alzheimer’s Disease has announced its Impact Factor has increased by 15 percent over last year’s number. The Impact Factor is “a measure reflecting the average number of citations to articles published in science and social science journals.” The journal is ranked 57th among 252 ranked journals in Neurosciences. For more on the JAD, go here.

Treatment That Protects Against Organ Transplant Rejection May Also Protect Against AD

Experts at the University of Texas at Galveston discovered that “individuals chronically treated with calcineurin inhibitors to prevent solid organ transplant rejection have a significantly lower incidence of AD/dementia as compared to the general population.” Their findings were published in the Journal of Alzheimer’s Disease. The researchers will continue to explore this premise further.

Amyloid Precursor Protein May Play Role in Eye and Muscle Health

Scientists say they have found that amyloid precursor protein, which is associated with the development of AD, may contribute to muscle and eye health. According to Jaehong Suh, Ph.D., a researcher involved in the work, “We hope the discoveries in this study would help to expand our understanding of the normal function of FE65 and APP. From this kind of very basic research, we may be able to find more clues for the causes of, and ultimately to discover effective treatments for, related human diseases such as cataract, congenital muscular dystrophies and Alzheimer’s disease.” It was published in The FASEB Journal.